Description:

A Phase III Trial of ZD4054 (Zibotentan) (Endothelin A Antagonist) in Non-metastatic Hormone Resistant Prostate Cancer (ENTHUSE M0) see http://clinicaltrials.gov/ct2/show/study/NCT00626548

Link:

http://clinicaltrials.gov/ct2/show/study/NCT00626548

Keywords:
Versions (4) ▾
  1. 11/22/11
  2. 11/22/11
  3. 3/27/14
  4. 4/13/14
Uploaded on:

April 13, 2014

DOI:
No DOI assigned. To request one pleaselog in.
License:
Creative Commons BY 4.0
Model comments:

You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.

Itemgroup comments for:

Item comments for:

In order to download data models you must be logged in. Please log in or register for free.

Eligibility DRKS00003883 NCT00626548 Prostate Cancer

Eligibility NCT00626548

  1. StudyEvent: Eligibility
    1. Eligibility NCT00626548
Inclusion criteria
18 Years and older
Male
Confirmed diagnosis of prostate cancer (adenocarcinoma of the prostate) that has NOT spread to the other parts of the body (metastases). Patients with lymph node involvement may be eligible if specified criteria is met.
Increasing Prostate Specific Antigen (PSA), collected within one year of enrollment
Currently receiving treatment with surgical or medical castration
Exclusion criteria
Currently using opiate based pain killers for cancer related pain
Previous treatment with chemotherapy (paclitaxel, docetaxel, and mitoxantrone). Prior targeted cancer therapies are permitted if received during a previous clinical trial
Suffering from heart failure or had a myocardial infarction within last 6 months
A history of epilepsy or seizures